Japan plans to buy AstraZeneca Plc’s experimental COVID-19 vaccine and fund a local company to manufacture Novavax’s vaccine candidate, ramping up its stockpile plan as it battles surging infections. Japan will order 120 million doses of the experimental vaccine developed by the British pharmaceutical company, beginning with 30 million doses by March next year. Separately, Takeda Pharmaceutical said on Friday it would manufacture and sell up to 250 million doses of Novavax’s COVID-19 vaccine candidate every year in Japan, with funding support from the government. …read more
Source:: Yahoo Finance
